Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralinepag Phase 2 Trial in Pulmonary Arterial Hypertension
NCT02279160Phase 2Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Dec 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Dec 2014; status: completed.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02279160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279160.